Arca Biopharma Rallies On New Plans For A Phase III Trial
By Brian L. Wilson : Arca Biopharma (NASDAQ
: ABIO ) was a very boring ticker in 2013 until the company provided an update on a proposed clinical trial for atrial fibrillation for the company's flagship drug Gencaro (bucindolol hydrochloride) after the closing bell on January 29th. The market's ...
Read the rest of this article on Long Investing Ideas from Seeking Alpha